Bob Colloton

Bob joined MIVI Neuroscience in 2018 as Chief Commercial Officer and was promoted to CEO in 2020. He is a proven leader in the medical device industry, bringing over 30 years of experience in a broad range of medical device companies from start-up organizations through publicly traded entities. Bob has extensive and applicable experience leading high-tech medical device organizations through product definition and invention, market approvals, market access, commercial launch and growth, organizational development, and strategic transactions including IPOs and M&A activities.

Throughout his career, Bob has demonstrated successful medical device corporate leadership. He was most recently Vice President of North America for Neuravi, which was acquired by Johnson and Johnson in 2017. Prior to that, Bob was Chief Commercial Officer for Revision Optics from 2010-2015, and from 2005-2010, he held the position of Vice President of Marketing and Sales for Micrus Endovascular (acquired by Johnson and Johnson). Bob has also held senior commercial positions for Scimed Life Systems, VNUS Medical, Transvascular, and Cardiometrics, along with additional roles at Ethicon/Johnson & Johnson and Microvasive/Boston Scientific.

Bob received a B.S. degree in Business from Miami University.

Location

Cupertino, United States

Links


Org chart


Teams


Offices

This person is not in any offices


MIVI Neuroscience

MIVI Neuroscience, (MIVI) is an innovative medical device company that aims to achieve life-giving results for an increasing number of patients experiencing acute ischemic stroke (AIS). We accomplish this through proprietary technology designed in collaboration with physicians to vastly improve the safety and efficacy of interventional AIS therapy.


Industries

Employees

11-50

Links